Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.6K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

906
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
906
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.6K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PulseSelect vs FARAPULSE pulsed field ablation: Comparative analysis of myocardial, neural-injury and hemolysis biomarkers and short-term outcomes.

International journal of cardiology. Heart & vasculature·2026
Same author

Computational modeling identifies protective mechanisms of estrogen and testosterone against atrial fibrosis.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Bile Acids Rewiring Cardiometabolic Systems.

The Canadian journal of cardiology·2026
Same author

Immunology of Cardiometabolic Health and Disease: From Novelty to Necessity.

The Canadian journal of cardiology·2026
Same author

Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The TRITAVI Registry.

JACC. Advances·2026
Same author

Potentially futile outcome after uncomplicated TAVI: Insights from the TRITAVI registry.

American heart journal·2026

Related Experiment Video

Updated: Mar 20, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.7K

Atrial-Selective Potassium Channel Blockers.

Niels Voigt1, Dobromir Dobrev1

  • 1Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Hufelandstr. 55, Essen 45122, Germany.

Cardiac Electrophysiology Clinics
|June 5, 2016
PubMed
Summary

Atrial fibrillation (AF) treatments are being explored through atrial-selective potassium channel blockers. These compounds target specific ion channels like IK,ACh and IKur, offering a novel therapeutic approach for AF.

Keywords:
Atrial fibrillationI(K,ACh)I(Kur)K2P channelsKv1.1 channelsSK channels

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K

Related Experiment Videos

Last Updated: Mar 20, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.7K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Electrophysiology

Background:

  • Atrial fibrillation (AF) significantly increases patient morbidity and mortality.
  • Targeting atrial-specific ion channels presents a novel therapeutic strategy for AF management.
  • Key atrial ion currents include IK,ACh and IKur, with other channels potentially contributing to atrial repolarization.

Purpose of the Study:

  • To review the molecular and electrophysiologic characteristics of atrial-selective potassium channels.
  • To explore the pathophysiologic role of these channels in atrial fibrillation.
  • To summarize existing potassium channel blockers relevant to AF treatment.

Main Methods:

  • Literature review focusing on atrial-selective potassium channels.
  • Analysis of molecular and electrophysiologic data.
  • Summary of current potassium channel blocker compounds.

Main Results:

  • Identification of IK,ACh and IKur as primary atrial-specific ion currents.
  • Discussion of the potential contribution of other K+ channels (e.g., two-pore domain, SK, Kv1.1) to atrial repolarization.
  • Overview of the characteristics and therapeutic potential of various K+ channel blockers.

Conclusions:

  • Atrial-selective potassium channels are crucial targets for novel AF therapies.
  • Understanding these channels' roles is key to developing effective AF treatments.
  • Further research into K+ channel blockers may yield improved therapeutic options for atrial fibrillation.